Technical Annex for the establishment of a COST Action
on Insulin resistance, obesity and diabetes mellitus in the elderly
A. Introduction
A.1. Today's status Diabetes mellitus is a frequent disease affecting
about 3% of individuals in western populations. Its incidence increases
regularly with age since it affects 10% of sixty years old individuals
and 20% of eighty years old individuals. Diabetes is a leading cause of
blindness, renal failure, and lower limb amputations in adults, and is
a major risk factor for cardiovascular disease and stroke. Its mortality
and morbidity is a considerable health burden of our society. To control
it, it is necessary to detect the persons who are predisposed in the population
and thus, to prevent the disease by adopting healthy and dietetic actions.
Although the pathogenesis of diabetes mellitus is not clear, several
metabolic abnormalities have been identified which contribute to hyperglycemia.
These include impaired insulin secretion, elevated rates of hepatic glucose
production and insulin resistance. Since diabetes mellitus is not a homogenous
entity, different causal mechanisms may exist in separate diabetes patient
groups. However, based on a variety of experimental approaches, it is clear
that insulin resistance is a prominent characteristic in these patients
and the contribution of insulin resistance to the manifestation of diabetes
in the elderly needs thorough investigations in order to develop new therapeutic
strategies.
The cellular mechanisms underlying insulin resistance have received
intensive study during the two last decades as our knowledge in the mechanism
of insulin action is increasing. The action of insulin is initiated by
its interaction with a specific transmembrane receptor tyrosine kinase.
The receptor is well-characterized, however, the immediate consequences
of its activation remain poorly defined. In one model, the activation of
the receptor-kinase leads to the tyrosine-phosphorylation of several substrates,
such as insulin receptor substrate-I to VI (IRS-I to IRS-VI), resulting
in the activation of a cascade of serine kinases, lipid kinases as well
as serine- and tyrosine-phosphatases. Binding of insulin to its receptor
also activates the MAP-kinase pathway and in addition to its metabolic
effects the hormone exerts key functions at the level of gene expression.
The signalling specificity between the insulin receptors and other tyrosine
kinase receptors, the role of specific insulin signalling pathways in different
tissues as well as their relevance to specific biological actions of insulin
is rather poorly defined.
Obesity is a major risk factor leading to the development of NIDDM.
Recent cloning of the ob-gene product, leptin and its receptor has provided
important insights to the molecular pathways regulating food intake and
energy expenditure leading to a considerable progress in understanding
the pathogenesis of obesity. The increasing research activities in the
leptin field strongly require a concerted European action to encourage,
coordinate and help the national efforts in this important and promising
area.
Diabetes mellitus has strong genetic determinants as shown by high concordance
for the disease in monozygotic twins and familial histories. The disease
is polygenic as its inheritance does not follow a Mendelian pattern. The
search for genes implicated in the pathogenesis of insulin resistance has
been possible as various candidate genes were examined. Efficient differential
screening methods have been also developed resulting in the discovery of
several diabetes-related genes, such as MODY1, MODY2 and MODY3, IRS-2,
Rad, PED/PEA-15, etc.
Diabetes mellitus of the aged people is most often described as non-insulin
depedent diabetes mellitus (NIDDM). However, detailed studies have established
other (sub-)classes, such as maturity onset diabetes of the young (MODY),
and demonstrated that an improved classification of diabetic patients is
urgently required.
In spite of all these information, our knowledge of the relationship
between structure and function of the insulin receptor, as well as the
molecular mechanisms of its downstream signalling is very much incomplete.
Similarly, the role of leptin and other exogenous factors which in combination
with a certain genetic background, predispose to the development of diabetes
need also further clarification.
A.2. Why the Cooperation should be Carried out
within the Context of COST?
The proposed Action is a logical consequence of COST Action B5 (1994-1999).
During COST Action B5 it became clear that diabetes mellitus of the aged
people is a more diverse disease as previously thought and can not be properly
described by the single term non-insulin dependent diabetes mellitus (NIDDM).
Besides insulin and IGF-signalling, leptin-dependent signalling mechanisms
became also important in the etiology of diabetes. Examination of numerous
candidate-genes emphasized the importance of differential screening methods
in further identification of diabetes-related genes. Therefore a significant
extension, total reformulation and restructuring of research in the field
became necessary. This urgent need is excellently served by the present
proposal. In parallel, the need and willingness for an all-European cooperation
in the area has significantly increased since 1994. COST can serve this
need excellently.
The proposed research action requires expertise in markedly different
areas of diabetes research and in different techniques, such as
-
the enzymology of protein phosphorylation and dephosphorylation,
-
structure/function relationships of insulin/leptin/IGF-1 receptors and
their substrates,
-
analysis of inositol-phospholipid-glycans, as insulin signalling molecules
and as potential drug-candidates
-
characterization of glucose transporters and related proteins
-
antibody production
-
analysis of mutations of insulin receptor and other candidate genes
-
search for genetic markers of diabetes by examining candidate genes, and
by using various differential screening techniques
-
clinical studies: clamp-studies, insulin action on monocytes and in aging,
etc.
This diverse expertise can be found and efficiently utilized only
via international cooperation. The fast development of the research action
requires a regular exchange of new scientific results/ideas and sharing
of research material and research techniques. This intensive multilateral
collaboration exceeds the forms of usual, informal collaborative research
and requires new, organized forms. The frames of a COST action would serve
these needs excellently.
A.3. How the proposed Action is related to other
international scientific programmes
During our project we will cooperate with the following related projects:
-
COST Action 918 on "Body weight and energy expenditure: functional foods".
The cooperation will utilize the different approaches taken by the two
Actions for the examination and extension of obesity-related genes. (Mutual
invitation to each other's meetings and information exchange is planned.)
-
BIOMED 2 programme "Search for NIDDM genes" (two members of the Steering
Committee of the BIOMED 2 programme were also involved in the formulation
of the present proposal; joint meetings and continuous information exchange
are planned).
-
International Institute on Ageing (United Nations, La Valetta, Malta; information
exchange is planned).
The precedessor of the present Action, COST B5 was a rich source of 5th
Framework applications and collaboration. However, the present COST Action
does not result in a parallel activity of the 5th Framework
program for the following reasons:
-
the present Action will be highly informal, flexible and interdisciplinary
-
there will be numerous countries involved in the Action, e.g. those from
Eastern and Southern Europe which are not often participating in 5th
Framework programmes
-
the involvement of the new Action in obesity and aging research together
with diabetes research will by itself ensure an interdisciplinary approach
a usual 5th Framework programme can not provide and
-
the involvement of local experts of others fields adds a further "interdisciplinary
element" to the Action.
B. Objectives and benefits
B.1. General objectives
Diabetes mellitus of aged people is a considerable health burden of western
societies. At present no widely established screening method is available
to detect the persons who are predisposed in the population and due to
our incomplete knowledge on the molecular mechanisms leading to NIDDM we
have very few means to influence the onset and development of this diverse
disease. The ongoing research of candidate genes as well as various differential
screening methods will be coordinated with the new Action.
Various steps of insulin action will be studied starting from the insulin
receptor and following insulin action till it reaches the cell nucleus
with special emphasis on the investigation of pathological changes of the
molecular mechanism of insulin action in insulin resistance, obesity and
NIDDM of the aged people. This research acitivity is thought to lead to
the development new drug-candidates for the curing-easing of the consequences
of this diverse disease.
B.2. Secondary objectives
The following steps of insulin action will be studied to gain a better
understanding of the etiology of insulin resistance, obesity and NIDDM
of the aged people, in hope to develop drug-candidates and a reliable screening
method to detect the individuals with inherited risk for the disease.
-
1. Identification of diabetogenes
-
1.1. examination of candidate genes
-
1.2. utilization of various differential screening methods
-
1.3. possible links of diabetes-related genes to insulin signalling
-
1.4. search for diabetes-related obesity genes
-
1.5. age-dependent analysis of critical genes
-
2. Studies on the intracellular mechanism of insulin action in normal and
pathological states
-
2.1. mechanism of the interactions between insulin receptor and its substrates,
analysis of tissue-specificity of insulin signalling pathways
-
2.2. molecular characterization of glucose transport in normal and insulin-resistant
states
-
2.3. molecular analysis of insulin signalling and action during the whole
lifespan
-
2.4. interrelationships of insulin resistance and leptin action
-
2.5. development of insulin- and leptin-related signalling molecules as
potential drug candidates
The list of secondary objectives is open for amendments incorporating the
specific aims of new goups willing to participate in the concerted action.
To join to the proposed research action an expertise in insulin (leptin,
insulin-like growth factor) dependent signal transduction, insulin resistance/obesity-related
physiological changes and/or in structural studies of insulin resistance/obesity-related
genes is required.
C. Scientific programme
To help and ensure the efficient information exchange and scientific research
cooperation between the participating research groups the following activities
are planned in the Action:
-
exchange of researchers between participating laboratories
-
organization of workshops, seminars and conferences
-
establishment of working groups studying the genetics, signalling, glucose
transport in insulin resistance, obesity ang ageing
-
organizing ways of continuous information exchange using an email correspondence
network and by informing the participants about each-other's scientific
achievements on a web-site.
A network will facilitate fast information exchange by electronic mail,
by a web-site on the Internet or by FAX. The web-site will contain an open
forum for "hot topics" and technical as well as theoretical discussions.
Conferences, workshops, working group meetings and seminars will be advertised
in the scientific community of the host country and will be open for interested
members to join. This will serve as a way to give direct information on
the Action and to popularize the idea of European collaboration in frame
of COST. Original results will be disseminated for the scientific community
by participating in international meetings of the network and organized
by other bodies and by communications in recognized scientific journals.
The Action will seek the possibilities to transfer the appropriate results
of the investigations to other networks and programmes such as the 5th
Framework programme or EUREKA. A partnership network will be organized
involving European companies in the field.
D. Organization and timetable
D.1. Organization and Management
A Management Committee will be set up following the signing by the appropriate
number of Signatories to the Memorandum of Understanding. This Committee
will work out its rules of operation at its first formal meeting in accordance
with existing COST regulations. The partners will appoint an Action Coordinator
who will be responsible for coordinating acitivities of the three to five
working groups (Genetics, Signalling, Glucose transport, Obesity, Ageing)
and ensuring that the Action meets the overall objectives. Annual reports
will be produced for the COST Senior Officials, and a detailed Final Report
will be written at the end of the five year period.
D.2. Timetable
The project is planned to last for five years. It is anticipated that the
research described in Section B. will be investigated in parallel, building
upon existing work in several countries. Specific time schedule and list
of tasks (including the organization of workshops) will be established
on a yearly basis by the Management Committee.
E. Economic dimension
in thousand ECU-s/year
E.1. Estimated personnel costs:
category A (50 scientists) 1.500
category B (25 technicians) 500
category C (40 students, secretaries) 500
E.2. Estimated running costs 1.940
E.3. Coordination costs 60
E.4. Total costs 4.5 mECU-s/year
Items E.1. and E.2. of the budget is covered from national sources in the
participating countries. E.3. is sought to be provided by the Commission.